UK-based biotech unicorn BenevolentAI just raised $115 million at a $2 billion valuation. The company uses artificial intelligence to help discover new drugs to treat conditions like Parkinson's disease and rare cancers. Applying artificial intelligence to drug discovery — which can often be a long, expensive process — has started attracting more attention from investors. BenevolentAI, a UK-based startup that uses artificial intelligence to discover new treatments just raised $115 million. The funding, which came from existing investors including Woodford Investment Management, values the six-year-old company at $2 billion, a unicorn status held by only a few biotech companies.